To evaluate pim1 inhibition as a therapeutic target for prostate cancer, particularly for myc-expressing tumors, the same authors examined the molecular consequences of pim1 and myc overexpression in the prostate and the effects of depleting pim1 in prostate carcinoma cells with high levels of myc. Here, PIM1 is linked to prostate cancer.